Skip to content

Evaluation of the effectiveness of systemic Echinacea on clinical indices of erosive oral lichen planus

Evaluation of the effectiveness of systemic Echinacea on clinical indices of erosive oral lichen planus

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20200223046591N1
Enrollment
64
Registered
2020-03-16
Start date
2019-08-03
Completion date
Unknown
Last updated
2020-03-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Erosive oral lichen planus. Lichen planus

Interventions

Intervention 1: Intervention group: Chracteristics of the consumed substance: Echinacea herbal tablets, The chemical composition and its concentration: Each tablet contains 114 mg of dried extract of
Consumption frequency: Three times a day orally, Consumption Duration: 35 days. one spoon of mouthwash: nystatin 100000 U/G 20-25 drops,4 ampule betamethasone suspension ,aluminium MG 1 spoon, diphen

Sponsors

Esfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 60 Years

Inclusion criteria

Inclusion criteria: Patients sufering from erosive oral lichen planus refered to isfahan dental school department of oral medicine whose lesions are clinically and pathologically confirmed according to WHO criteria Certaining of the patient's cooperation and consent presence of at least one lichen planus lesion in oral cavity according to modified Thongprasom criteria the clinical score must be more than 1

Exclusion criteria

Exclusion criteria: patients attended another clinical trial in past 3 months pregnancy and lactation presence of lichenoid reactions presence of extraoral lesions use of systemic steroid drugs, analgesics, immunomodulation drugs, NSAIDs a week before trial presence of other lesions in oral cavity history of asthma and allergy patients suffering from systemic conditions such as diabetes, TB, high blood pressure, life threatening diseases and cancer patients suffering from ulcerative colitis, entrogastric diseases, crohns syndrome, behjet`s syndrome, intensive anemia, rheumatoid arthritis, lupus, multiple sclerosis, collagen disorders, leukosis and AIDS history of organ transplantation

Design outcomes

Primary

MeasureTime frame
Lesion size. Timepoint: At baseline(before intervention),10,25 and 35 days after using Echinacea tablets. Method of measurement: graph paper and ruler.;Pain level. Timepoint: At baseline(before intervention),10,25 and 35 days after using Echinacea tablets. Method of measurement: Visual Analogue Scale index.

Secondary

MeasureTime frame
Duration of lesion healing. Timepoint: At baseline(before intervention),10,25 and 35 days after using Echinacea tablets. Method of measurement: day.;Duration of pain relief. Timepoint: At baseline(before intervention),10,25 and 35 days after using Echinacea tablets. Method of measurement: day.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZahra Saberi

Esfahan University of Medical Sciences

zahra.saberi@dnt.mui.ac.ir+98 31 3792 5514

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026